InvestorsHub Logo
Followers 62
Posts 24636
Boards Moderated 0
Alias Born 11/23/2016

Re: dadbrotheroftwins post# 283972

Wednesday, 11/18/2020 6:38:57 PM

Wednesday, November 18, 2020 6:38:57 PM

Post# of 472913
Even if endpoints are not met in a phase 2 trial, a P3 can be designed based on the data and agreed with the FDA. For that the PDD P2 readout we have seen is great.

No approval until P3 trial endpoints are met and no meaningful SP improvement from the PDD P2 data to date.

SP might increase with the analysis and release of the full PDD P2 data or from Rett readouts. Otherwise will be late 2022 or into 2023 for next hope of getting rich.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News